%0 Journal Article
%T Personalized Statin Therapy and Coronary Atherosclerotic Plaque Burden in Asymptomatic Low/Intermediate-Risk Individuals
%A Ahmed Hamimi
%A Ahmed M. Gharib
%A Colleen Hadigan
%A Jatin Raj Matta
%A Khaled Z. Abd-Elmoniem
%A Lynnette K. Nieman
%A Radwa A. Noureldin
%A Ranganath Muniyappa
%A Riham H. El Khouli
%A Siri Ranganath
%J Archive of "Cardiorenal Medicine".
%D 2018
%R 10.1159/000487205
%X Current guidelines for the primary prevention of atherosclerotic cardiovascular disease are based on the estimation of a predicted 10-year cardiovascular disease risk and the average relative risk reduction estimates from statin trials. In the clinical setting, however, decision-making is better informed by the expected benefit for the individual patient, which is typically lacking. Consequently, a personalized statin benefit approach based on absolute risk reduction over 10 years (ARR10 benefit threshold ¡Ý2.3%) has been proposed as a novel approach. However, how this benefit threshold relates with coronary plaque burden in asymptomatic individuals with low/intermediate cardiovascular disease risk is unknown
%K Atherosclerosis
%K Coronary computed tomography angiography
%K Personalized therapy
%K Statin therapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968283/